These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 18206857)

  • 21. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L;
    Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
    Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
    Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task.
    Bush G; Spencer TJ; Holmes J; Shin LM; Valera EM; Seidman LJ; Makris N; Surman C; Aleardi M; Mick E; Biederman J
    Arch Gen Psychiatry; 2008 Jan; 65(1):102-14. PubMed ID: 18180434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study.
    Casas M; Rösler M; Sandra Kooij JJ; Ginsberg Y; Ramos-Quiroga JA; Heger S; Berwaerts J; Dejonckheere J; van der Vorst E; Schäuble B
    World J Biol Psychiatry; 2013 May; 14(4):268-81. PubMed ID: 22106853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?
    Sumner CR; Haynes VS; Teicher MH; Newcorn JH
    Postgrad Med; 2010 Sep; 122(5):52-61. PubMed ID: 20861588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Greenhill LL; Muniz R; Ball RR; Levine A; Pestreich L; Jiang H
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):817-23. PubMed ID: 16832318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
    Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
    Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
    Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
    Rösler M; Retz W; Fischer R; Ose C; Alm B; Deckert J; Philipsen A; Herpertz S; Ammer R
    World J Biol Psychiatry; 2010 Aug; 11(5):709-18. PubMed ID: 20353312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE
    Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
    Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
    Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer.
    Mulhern RK; Khan RB; Kaplan S; Helton S; Christensen R; Bonner M; Brown R; Xiong X; Wu S; Gururangan S; Reddick WE
    J Clin Oncol; 2004 Dec; 22(23):4795-803. PubMed ID: 15570081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder.
    Herring WJ; Wilens TE; Adler LA; Baranak C; Liu K; Snavely DB; Lines CR; Michelson D
    J Clin Psychiatry; 2012 Jul; 73(7):e891-8. PubMed ID: 22901359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.
    Zheng Y; Wang YF; Qin J; Wang LW; Zou LP; Jin XM; Xu T; Wang Y; Qi YL; Gong ME; Yin QY; Mai JN; Jing J; Luo XY; Ma HW; Li HB; Xie L; Li Y; Kuang GF; Yi MJ; Wang F; Zhu XH; Yao YB
    Chin Med J (Engl); 2011 Oct; 124(20):3269-74. PubMed ID: 22088519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate.
    Rösler M; Ginsberg Y; Arngrim T; Adamou M; Niemelä A; Dejonkheere J; van Oene J; Schäuble B
    World J Biol Psychiatry; 2013 May; 14(4):282-90. PubMed ID: 21517701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder.
    Manor I; Ben-Hayun R; Aharon-Peretz J; Salomy D; Weizman A; Daniely Y; Megiddo D; Newcorn JH; Biederman J; Adler LA
    J Clin Psychiatry; 2012 Dec; 73(12):1517-23. PubMed ID: 23290324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
    J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.